Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Completed 12Terminated 3Recruiting 3Unknown 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Genitourinary 1Breast 1

Conditions

Prostatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 144Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Terminated × Vaccines × Clear all
NCT06175221 2025-09-15

Autologous TLPO Vaccine Basket

Elios Therapeutics, LLC

Phase 2 Terminated
63 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT03630809 2022-04-25

Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
16 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT02362451 2022-03-18

Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
7 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡